Stay up to date with the latest stock market news from around the world. From breaking news written by our finance analysts to event-driven market news on a global scale.
This week’s picks cover: How UPS plans to cut costs and automate its way back to profitability, why Paradigm Biopharma could soar if its osteoarthritis drug wins FDA approval, and how Barrick Mining offers a hedge against U.S. fiscal chaos
Rexford Industrial Realty (REXR) reported net profit margins of 32.9%, up from 29.3% last year, highlighting robust profitability. While the company’s earnings have grown at an impressive 29.3% per year over the past five years, growth cooled to 23.8% in the most recent year. Future projections indicate a 1.6% annual earnings decline and 5.1% revenue growth, which lags behind the broader US market. Results were buoyed by an $80.1 million one-off gain, and the shares currently trade at $43.41,...
Valmont Industries (VMI) reported net profit margins of 6.3%, down from 7.3% last year, as current results reflect the impact of a one-off loss of $101.4 million over the last twelve months. The company is forecasting earnings growth of 16.2% per year, outpacing the US market’s 15.5% average, while revenue is expected to grow 3.5% annually compared to the industry’s 10.1%. With these projections, investors are likely to focus on Valmont’s path to regaining margin strength and monitoring its...
Acme United (ACU) reported a net profit margin of 5.3%, marking a decline from last year’s 10.1%. Negative earnings growth over the past year contrasts with its five-year average annual earnings increase of 9.4%. With revenue forecast to rise just 4.8% per year and earnings expected to fall 15.9% annually over the next three years, investors are scrutinizing the company’s weaker margins and muted prospects. The P/E ratio stands at 13.9x and the share price is $37.75, both below industry and...
First United (FUNC) reported standout earnings growth of 54.4% over the past year, far outpacing its 5-year average of 5.3% per year. Net profit margins reached 29.8%, rising from 22.7% in the prior year, while shares are currently trading at $36.98, well below an estimated fair value of $68.47. With only one minor risk flagged and multiple rewards highlighted, including high-quality past earnings, expanding profit and revenue, and a strong value profile, the latest results point to improved...
Perspective Therapeutics revealed updated interim results from its Phase 1/2a trial of [212Pb]VMT-alpha-NET at ESMO Congress 2025, which sparked a sharp drop in the company’s share price as investors digested the latest efficacy signals.
See our latest analysis for Perspective Therapeutics.
This latest clinical trial update comes after a challenging year for Perspective Therapeutics. Following a brief rally in anticipation of new data, the 1-day share price return slipped by 2.5%, and the...
On October 13, 2025, SQ Innovation received FDA approval for Lasix ONYU, a combination product featuring Gerresheimer’s proprietary on-body infusor for at-home subcutaneous drug delivery in select congestive heart failure patients.
This milestone showcases Gerresheimer’s technological capabilities in advanced drug delivery devices and highlights its growing position as a full-service partner to pharmaceutical companies embracing home-based care.
Next, we’ll explore how the FDA-backed rollout...
Artiva Biotherapeutics recently announced that the FDA has granted Fast Track Designation to its AlloNK (AB-101) therapy in combination with rituximab for the treatment of refractory rheumatoid arthritis, marking a first for deep B-cell depleting therapies in this indication.
This development highlights Artiva's focus on addressing a large unmet need in autoimmune disease with an outpatient-ready, community-administered cellular therapy.
We'll explore how Fast Track status for AlloNK and...
Amid ongoing global market volatility and economic uncertainties, Asian markets have been navigating a complex landscape marked by trade tensions and fluctuating investor sentiment. In this environment, identifying undervalued stocks can offer potential opportunities for investors seeking value; these stocks may be trading below their intrinsic worth due to broader market conditions rather than company-specific issues.
Freelance.com (ENXTPA:ALFRE) delivered earnings growth of 53.2% over the past year, outpacing its robust five-year average annual growth rate of 20.2%. Net profit margins improved to 2.2% from 1.6% a year ago, while the stock trades at €2.22, a notable discount to its estimated fair value of €9.02 and well below peer valuation multiples. While recent results highlight consistently high-quality earnings and increasing profitability, the major risk for investors is the projected 0.3% annual...
